Amir Hefni

Amir is the CEO of Resolution Therapeutics. Previously, he was Head of Global Cell and Gene Therapy at Novartis where he was reponsible for the company’s global product development, manufacturing, supply chain and commercialisation of innovative cell and gene therapies. He has also held the role of Global Asset Head in Oncology at Ipsen and Executive Director US Oncology at Bristol-Myers Squibb. Amir holds a BSc and PhD in Pharmacology from King’s College London and an MBA from Warwick Business School. He is a Board Director of Lift Biosciences and MedUniverse.